Eagle Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance
Eagle Pharmaceuticals, Inc. had Deferred Tax Assets, Valuation Allowance of $35.10 million as of 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2023-03-23
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $35.10M.
- 2021-12-31: Deferred Tax Assets, Valuation Allowance $4.96M.
- 2020-12-31: Deferred Tax Assets, Valuation Allowance $3.07M.
- 2019-12-31: Deferred Tax Assets, Valuation Allowance $951.00K.
| Period end | Deferred Tax Assets, Valuation Allowance | Deferred Tax Assets, Valuation Allowance as first filed |
|---|---|---|
| 2022-12-31 | $35.10M 10-K · filed 2023-03-23 | |
| 2021-12-31 | $4.96M 10-K · filed 2023-03-23 | |
| 2020-12-31 | $3.07M 10-K · filed 2022-03-08 | |
| 2019-12-31 | $951.00K 10-K · filed 2021-03-05 | |
| 2018-12-31 | $0.00 10-K · filed 2020-03-02 | |
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 | |
| 2016-12-31 | $0.00 10-K · filed 2018-02-26 | |
| 2015-12-31 | $38.52M 10-K · filed 2017-03-15 | |
| 2014-12-31 | $40.18M 10-K · filed 2016-02-29 | |
| 2014-09-30 | $38.25M 10-K · filed 2016-02-29 | -$38.25M 10-K · filed 2014-12-22 |
| 2013-09-30 | $32.77M 10-K · filed 2016-02-29 | -$32.77M 10-K · filed 2014-12-22 |